A Randomized, Placebo-Controlled Phase 2 Study to Evaluate the Safety and Efficacy of CLF065 in the Treatment of Chronic Pouchitis

Inclusion Criteria: 1. Adult subjects aged 18-80 years, inclusive. 2. In the opinion of the investigator, the subject is capable of understanding and complying with protocol requirements. 3. The subject signs and dates a written, informed consent form and any required privacy authorization prior to the initiation of any study procedures. 4. Diagnosis of pouchitis that is recurrent, defined by mPDAI score of ≥ 5 assessed as the average from 3 days immediately prior to Baseline endoscopy, and a minimum endoscopic subscore of 2 (outside the staple or suture line) with either: ≥ 3 episodes of…